Last reviewed · How we verify
NCT06346912
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
EARLY_PHASE1 trial testing CD19-BAFF Targeted CAR T-cells in Acute Lymphoblastic Leukemia,B-Cell in 20 participants. Currently enrolling.
30 May 2027
Quick facts
| Lead sponsor | Zhejiang University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 30 May 2024 |
| Primary completion | 30 May 2027 |
| Estimated completion | 30 May 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD19-BAFF Targeted CAR T-cells — full drug profile →
Conditions studied
- Acute Lymphoblastic Leukemia,B-Cell — all drugs for Acute Lymphoblastic Leukemia,B-Cell →
- Non-hodgkin Lymphoma,B Cell — all drugs for Non-hodgkin Lymphoma,B Cell →
Sponsor
Zhejiang University
Who can join
18 and older, any sex, with Acute Lymphoblastic Leukemia,B-Cell or Non-hodgkin Lymphoma,B Cell. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for refractory/relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108 -
Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation.
Nayyar M, Menezes RCB, Ailawadhi S, Parrondo RD. · · 2025 · cited 2× · PMID 40723181 · DOI 10.3390/cancers17142298
Verify or expand the search:
- PubMed search for NCT06346912
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CD19-BAFF Targeted CAR T-cells
Trials testing the same drug.
- NCT06279923 — CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases · EARLY_PHASE1 · recruiting
Other Zhejiang University trials
Trials by the same sponsor.
- NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
- NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
- NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
- NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06346912 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
- Last refreshed: 14 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06346912.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing